The FTC has initiated a series of warning letters targeting pharmaceutical companies to challenge numerous patent listings in the Orange Book, aiming to facilitate greater consumer access to generic drugs. With the new Republican leadership, the agency continues its push against improper patent listings that it sees as anti-competitive. Specifically, the letters focus on various inhaler and drug delivery device patents, while the pharmaceutical sector continues to request clearer guidelines for patent listings. This effort might lead to prolonged litigation outside of the established timelines of the Hatch-Waxman Act, complicating market dynamics for generic drugs.
The FTC's recent letter campaign could result in prolonged litigation beyond Hatch-Waxman timelines, impacting patent validity and consumer access to generics.
In its efforts to enhance generic drug accessibility, the FTC challenges numerous patent listings in the Orange Book, continuing its initiative from the previous administration.
The latest FTC letters confront patents in inhalers and drug delivery devices, while the pharmaceutical industry seeks clearer guidelines for listing such patents.
Targeting 200 patent listings across 17 NDAs, the FTC's actions signify a persistent push against improper patent listings perceived as anti-competitive.
Collection
[
|
...
]